The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Pembrolizumab plus enzalutamide for enzalutamide-resistant metastatic castration-resistant prostate cancer (mCRPC): Updated analyses after one additional year of follow-up from cohorts 4 and 5 of the KEYNOTE-199 study.
 
Julie N Graff
Honoraria - Astellas Medivation; Bayer; Bayer; Bayer; Janssen Oncology; Janssen Oncology; Janssen Oncology; Janssen Oncology; Sanofi; Valeant/Dendreon
Consulting or Advisory Role - Exelixis
Speakers' Bureau - i3 CME; Plexus; Plexus
Research Funding - Janssen Oncology (Inst); Medivation (Inst); Merck Sharp & Dohme (Inst); Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - Oncoresponse: Exceptional responders
Travel, Accommodations, Expenses - Bayer; Clovis Oncology; Merck Sharp & Dohme; Merck Sharp & Dohme; Sanofi
 
Scott T. Tagawa
Consulting or Advisory Role - 4D Pharma; Abbvie; AIkido Pharma; Amgen; Astellas Pharma; Bayer; Blue Earth Diagnostics; Clovis Oncology; Dendreon; Endocyte; Genentech; Genomic Health; Immunomedics; Janssen; Karyopharm Therapeutics; Medivation; Novartis; Pfizer; POINT Biopharma; QED Therapeutics; Sanofi; Seagen; Tolmar
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AVEO (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Dendreon (Inst); Endocyte (Inst); Exelixis (Inst); Genentech (Inst); Immunomedics (Inst); Inovio Pharmaceuticals (Inst); Janssen (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Medivation (Inst); Merck (Inst); Millennium (Inst); Newlink Genetics (Inst); Novartis (Inst); POINT Biopharma (Inst); Progenics (Inst); Rexahn Pharmaceuticals (Inst); Sanofi (Inst); Stem CentRx (Inst)
Travel, Accommodations, Expenses - Amgen; Immunomedics; Sanofi
(OPTIONAL) Uncompensated Relationships - ATLAB Pharma; Phosplatin Therapeutics; Telix Pharmaceuticals
 
Christopher J. Hoimes
Honoraria - Seagen
Consulting or Advisory Role - 2bPrecise; Bristol-Myers Squibb; Eisai; Genentech/Roche; Merck Sharp & Dohme; Prometheus; Seagen
Speakers' Bureau - Astellas Pharma; Bristol-Myers Squibb; Eisai; Genentech/Roche; Seagen
Research Funding - Merck Sharp & Dohme; Merck Sharp & Dohme (Inst)
(OPTIONAL) Uncompensated Relationships - 2bPrecise (Inst)
 
Winald R. Gerritsen
Consulting or Advisory Role - Bristol-Myers Squibb (Inst); IMS Health (Inst); Janssen-Cilag (Inst); MSD (Inst); Sanofi (Inst)
Speakers' Bureau - ESMO (Inst); MSD (Inst)
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Janssen-Cilag (Inst); Sanofi (Inst)
 
Ulka N. Vaishampayan
Honoraria - Bayer; Bristol-Myers Squibb; Exelixis; Pfizer; Sanofi
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; EMD Serono; Exelixis; Pfizer
Speakers' Bureau - Bayer; Bristol-Myers Squibb; Eisai; Exelixis; Pfizer; Sanofi
Research Funding - Astellas Pharma; Bristol-Myers Squibb; Exelixis; Pfizer
 
Tony Elliott
No Relationships to Disclose
 
Clara Hwang
Stock and Other Ownership Interests - Johnson & Johnson/Janssen (I)
Consulting or Advisory Role - Genzyme
Research Funding - AstraZeneca (Inst); Bausch Health (Inst); Bayer (Inst); Genentech (Inst); Merck (Inst)
Travel, Accommodations, Expenses - Merck
 
A. J. Ten Tije
No Relationships to Disclose
 
Aurelius Omlin
Consulting or Advisory Role - Astellas Pharma (Inst); Bayer (Inst); Janssen (Inst); Molecular Partners (Inst); MSD (Inst); Roche (Inst); Sanofi (Inst)
Speakers' Bureau - Astellas Pharma (Inst); Bayer (Inst); Janssen-Cilag (Inst)
Research Funding - Janssen (Inst); Teva (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; Bayer; Janssen; Sanofi
 
Raymond S. McDermott
Honoraria - Astellas Pharma; Bayer; Bristol-Myers Squibb; Clovis Oncology; Janssen; Merck Sharp & Dohme; Novartis; Pfizer; Sanofi
Speakers' Bureau - MSD Oncology
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Janssen (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Ipsen; Janssen-Cilag; Pfizer; Roche
 
Yves Fradet
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; AstraZeneca/MedImmune; Ferring; Janssen-Ortho; Merck; Roche Canada; Sanofi; TerSera
Research Funding - Astellas Pharma; IMV (Inst); Merck (Inst)
Travel, Accommodations, Expenses - Sanofi; TerSera
 
Deepak Kilari
Honoraria - Exelixis
Consulting or Advisory Role - Exelixis; Merck Sharp & Dohme; Myovant Sciences; Sanofi
Speakers' Bureau - Astellas Pharma; Exelixis; Genzyme; Genzyme (Inst); Janssen
Research Funding - Astellas Pharma (Inst); Exelixis (Inst); Genentech (Inst)
Travel, Accommodations, Expenses - Bayer; Clovis Oncology; Exelixis; Janssen; Sanofi
 
Cristiano Ferrario
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Merck; Novartis; Pfizer; Roche Canada
Consulting or Advisory Role - AstraZeneca; Bayer; Genomic Health; Merck; Odonate Therapeutics
Speakers' Bureau - Merck
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer; Bicycle Therapeutics (Inst); Immunomedics (Inst); Janssen Oncology (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst); Sanofi (Inst); Seagen (Inst); Sermonix Pharmaceuticals (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - Novartis; Roche
 
Hiroji Uemura
Honoraria - Astellas Pharma; Bayer Yakuhin; Janssen Oncology; Sanofi; Takeda
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; AstraZeneca; Bayer Yakuhin; Janssen Oncology; Takeda
 
Cuizhen Niu
Employment - Merck
Travel, Accommodations, Expenses - Merck
 
Christian Heinrich Poehlein
Employment - Merck
Leadership - Merck
Stock and Other Ownership Interests - Merck
Travel, Accommodations, Expenses - Merck
 
Ronald De Wit
Honoraria - Merck Sharp & Dohme; Sanofi
Consulting or Advisory Role - Astellas Pharma; Bayer; Janssen; Merck Sharp & Dohme; Sanofi
Research Funding - Bayer (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Bayer
 
Charles Schloss
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Johann S. De Bono
Employment - Institute of Cancer Research
Honoraria - Amgen; Astellas Pharma; Astex Pharmaceuticals; AstraZeneca; Bayer; BioExcel; Boehringer Ingelheim; Celgene; CellCentric; Daiichi Sankyo; Eisai; Genentech/Roche; Genmab; GlaxoSmithKline; Harpoon; Janssen Oncology; Medivation; Menarini Silicon Biosystems; Merck Serono; Merck Sharp & Dohme; Orion; Pfizer; Qiagen; Sanofi; Sierra Oncology; Taiho Pharmaceutical; Terumo; Vertex
Consulting or Advisory Role - Amgen; Astellas Pharma; Astellas Pharma; AstraZeneca; Bayer; BioXCel therapeutics; Boehringer Ingelheim; CellCentric; Daiichi Sankyo; Eisai; Genentech/Roche; Genmab; GlaxoSmithKline; Harpoon; Janssen Oncology; Menarini Silicon Biosystems; Merck Serono; Merck Sharp & Dohme; Orion; Pfizer; Qiagen; Sanofi; Sanofi Aventis GmbH; Sierra Oncology; Taiho Pharmaceutical; Terumo; Vertex
Research Funding - Amgen; Astellas Pharma; Astex Pharmaceuticals; AstraZeneca; Bayer; CellCentric; Daiichi Sankyo; Genentech/Roche; Genmab; GlaxoSmithKline; Harpoon; Janssen; Menarini Silicon Biosystems; Merck Serono; Merck Sharp & Dohme; Orion; Pfizer; Sanofi; Sanofi Aventis GmbH; Sierra Oncology; Taiho Pharmaceutical; Vertex
Patents, Royalties, Other Intellectual Property - Abiraterone Rewards to Inventors (Inst); CHK1 inhibitor (Inst); PARP inhibitors and DNA repair defects (Inst); Targeting of IL23 in prostate cancer (Inst)
Travel, Accommodations, Expenses - Amgen; Astellas Pharma; AstraZeneca; Bayer; BioXCel therapeutics; Boehringer Ingelheim; Cellcentric; Daiichi Sankyo; Eisai; Genentech/Roche; Genmab; GlaxoSmithKline; Harpoon; Janssen; Menarini Silicon Biosystems; Merck Serono; Merck Sharp & Dohme; Orion; Pfizer; Qiagen; Qiagen; Sanofi; Sierra Oncology; Taiho Pharmaceutical; Terumo; Vertex
 
Emmanuel S. Antonarakis
Honoraria - Astellas Pharma; AstraZeneca; Clovis Oncology; Dendreon; ESSA; Janssen Biotech; Medivation; Merck; Sanofi
Consulting or Advisory Role - AstraZeneca; Bayer; Clovis Oncology; Dendreon; ESSA; Janssen Biotech; Lilly; Merck; Sanofi
Research Funding - Aragon Pharmaceuticals (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Clovis Oncology (Inst); Constellation Pharmaceuticals (Inst); Dendreon (Inst); Exelixis (Inst); Genentech (Inst); Janssen Biotech (Inst); Johnson & Johnson (Inst); Merck (Inst); Millennium (Inst); Novartis (Inst); Sanofi (Inst); Tokai Pharmaceuticals (Inst)
Patents, Royalties, Other Intellectual Property - Co-inventor of a biomarker technology that has been licensed to Qiagen
Travel, Accommodations, Expenses - Dendreon; Medivation; Sanofi